- Home
- XPON vs JAGX Comparison
XPON vs JAGX Comparison
Compare XPON & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XPON
- JAGX
- Stock Information
- Founded
- XPON 2016
- JAGX 2013
- Country
- XPON United States
- JAGX United States
- Employees
- XPON N/A
- JAGX N/A
- Industry
- XPON Electronic Components
- JAGX Biotechnology: Pharmaceutical Preparations
- Sector
- XPON Technology
- JAGX Health Care
- Exchange
- XPON Nasdaq
- JAGX Nasdaq
- Market Cap
- XPON 3.2M
- JAGX 3.5M
- IPO Year
- XPON 2022
- JAGX N/A
- Fundamental
- Price
- XPON $0.83
- JAGX $2.58
- Analyst Decision
- XPON
- JAGX Strong Buy
- Analyst Count
- XPON 0
- JAGX 1
- Target Price
- XPON N/A
- JAGX $60.00
- AVG Volume (30 Days)
- XPON 54.1K
- JAGX 90.6K
- Earning Date
- XPON 08-13-2025
- JAGX 08-12-2025
- Dividend Yield
- XPON N/A
- JAGX N/A
- EPS Growth
- XPON N/A
- JAGX N/A
- EPS
- XPON N/A
- JAGX N/A
- Revenue
- XPON $6,702,411.00
- JAGX $11,552,000.00
- Revenue This Year
- XPON $61.26
- JAGX $22.41
- Revenue Next Year
- XPON N/A
- JAGX $30.00
- P/E Ratio
- XPON N/A
- JAGX N/A
- Revenue Growth
- XPON 23.07
- JAGX 13.93
- 52 Week Low
- XPON $0.60
- JAGX $2.43
- 52 Week High
- XPON $120.00
- JAGX $110.75
- Technical
- Relative Strength Index (RSI)
- XPON 43.08
- JAGX 28.76
- Support Level
- XPON $0.81
- JAGX $2.61
- Resistance Level
- XPON $0.97
- JAGX $3.30
- Average True Range (ATR)
- XPON 0.08
- JAGX 0.28
- MACD
- XPON -0.01
- JAGX 0.06
- Stochastic Oscillator
- XPON 18.57
- JAGX 6.56
About XPON Expion360 Inc.
Expion360 Inc is focused on the design, assembly, manufacturing, and sales of lithium iron phosphate (LiFePO4) batteries and supporting accessories for recreational vehicles (RV's) and marine applications with plans to expand into home energy storage products and industrial applications. Its product offerings include some of the minimal-footprint batteries in the RV & Marine industry.
About JAGX Jaguar Health Inc.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.